Insider trade

CFO received an award of 28K ABT shares

Traded Feb 24, 2026 · Filed Feb 26, 2026

Abbott LaboratoriesABT

28K
Shares

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 24, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 26, 2026

CFOGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references tax withholding

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001805099-26-000002
Filed / recorded

Feb 26, 2026, 10:46 PM UTC

Added to OQRO

Oct 2, 2026, 12:26 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

ABBOTT LABORATORIES

Issuer CIK

1800

Ticker

ABT

Reporting person

Philip P Boudreau

Relationship

Officer

Officer title

EVP AND CFO

Security

Common shares without par value

Table

Non-derivative (Table I)

Transaction date

Feb 24, 2026

Transaction code

A

Shares / units

27,997

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

78,613

Ownership form

Direct

Amendment

No

Footnotes from the filing

These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.